Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

Genmab Reports Financial Results for the 12 Months Ended December 31, 2007

COPENHAGEN, Denmark, March 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today results for the financial year ended December 31, 2007.

Revenues of DKK 530 million (approximately USD 104 million) compared to DKK 136 million (approximately USD 27 million) in 2006.

An Operating Loss of DKK 437 million (approximately USD 86 million). This compares to an Operating Loss of DKK 472 million (approximately USD 93 million) reported in 2006.

Net Financial Income totaled DKK 54 million (approximately USD 11 million) compared to Net Financial Income of DKK 34 million (approximately USD 7 million) in 2006.

A Net Loss of DKK 383 million (approximately USD 76 million) compared to a Net Loss in 2006 of DKK 438 million (approximately USD 86 million). The Net Loss per share was DKK 8.72 (approximately USD 1.72) in 2007 compared to a Net Loss per share of DKK 11.26 (approximately USD 2.22) in 2006. The 2007 Net Loss exceeded Genmab's guidance of DKK 260 to 310 million as a development milestone payment projected for late 2007 was not received until January 2008. The milestone payment of DKK 87 million was triggered by the first patient receiving treatment in the HuMax-CD20 (ofatumumab) Phase III rheumatoid arthritis (RA) program.

Genmab ended the year with a cash position of DKK 3.7 billion (approximately USD 728 million), which is an increase of approximately DKK 2.0 billion (approximately USD 388 million) from the end of 2006.

USD 1.00 = DKK 5.075 (Danish Central Bank's spot rate on December 31, 2007)

2007 Highlights:

Genmab achieved a number of business and scientific milestones, as follows:

Partnership progress:

Genmab and GlaxoSmithKline received antitrust clearance for the

HuMax-CD20 co-development and commercialization agreement; achieved first

two milestones in collaboration

Achieved
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... AZ (PRWEB) July 31, 2014 Sales ... availability of its online sales training course – ... improve their sales performance. , Drawn from proven sales ... 500 companies, Mastering the Complex Sale online sales training ... to anyone who has face-to-face contact with customers, like ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... and NYSE: SNY) today announced that the Companies intend ... rare pediatric disease priority review voucher in connection with ... priority review voucher entitles the holder to designate a ... 6-month review from the filing date instead of the ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources Group ... medical directors in the United States ... biosimilar market penetration will be the level of ... and the expected lower cost to patients. Payers ... that meet their pricing expectations in order to ...
(Date:7/30/2014)... 30, 2014  The Chicago Bears are excited to ... Dermatology (Academy) in an effort to raise awareness of ... host free SPOT me™ skin cancer screenings at a ... Field. SPOT me™ is an educational campaign designed ... and risks of skin cancer, and encourages people to ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4
... March 23, 2011 Advanced Cell Technology, Inc. ("ACT"; ... in the field of regenerative medicine, announced today that ... Company,s patent application to provide broad intellectual property protection ... retinal pigment epithelial (RPE) cells from human embryonic stem ...
... of survival tend to favor the strongest, but University ... world of self-healing materials, it is the somewhat frail ... Langmuir a new model laying out the ... particles that can regenerate after taking damage and are ...
... NEOG ) announced today that its net income ... 28, increased 27% from the previous year to $4,943,000 — ... $0.17 per share. Third quarter revenues increased ... company, compared to the prior year,s $33,833,000. Year to date, ...
Cached Biology Technology:ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 2ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 3Only the weak survive?: Pitt team adds more give for stronger self-healing materials 2Neogen Reports 27% Increase in Quarterly Net Income 2Neogen Reports 27% Increase in Quarterly Net Income 3Neogen Reports 27% Increase in Quarterly Net Income 4Neogen Reports 27% Increase in Quarterly Net Income 5Neogen Reports 27% Increase in Quarterly Net Income 6
(Date:7/30/2014)... Antonio Life Sciences Institute (SALSI), a joint venture between ... The University of Texas Health Science Center at San ... Pilot Program. The winners, Emily Boice from UTSA and ... $25,000 for their project titled, "Novel engineered ferritins for ... , Boice and Huang,s research is focused on finding ...
(Date:7/30/2014)... baboons suggests that the route to a higher rank is ... of supportive sisters. , A female baboon,s social status is ... of her mother - the higher the mother is ranked, ... rank in female baboons is thought to be determined at ... spot in the pecking order, whereas females born to low-ranking ...
(Date:7/30/2014)... University associate professor Andrew S. Mount, performed cutting-edge research ... for novel anti-fouling paint for ships and boats and ... The team,s findings, published in Nature Communications ... that attaches to a wide variety of surfaces using ... an underwater heavy-duty adhesive. , "In previous research, we ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... PHILADELPHIA The second American Association for Cancer ... Research: From the Laboratory to the Clinic provides attendees ... in a variety of fields, including the tumor microenvironment, ... takes place March 7-10, 2010, at the King Hussein ...
... of America is pleased to announce the 2010 Yeast ... at the University of British Columbia (UBC) in Vancouver, ... various aspects of eukaryotic biology in yeast. Program ... Canadian astronaut who is also a Member of Parliament. ...
... Texas Imagine a mosquito-borne virus that has already infected ... Asia, the islands of the Indian Ocean, Africa and northern ... that can linger for months or even years. It,s capable ... much of North America. And no vaccine or treatment exists ...
Cached Biology News:The AACR to host second cancer research conference in Jordan 22010 Yeast Genetics and Molecular Biology Meeting 22010 Yeast Genetics and Molecular Biology Meeting 3Experimental vaccine protects monkeys against chikungunya 2
... - Proliferation Marker, prediluted Ki67 antigen ... protein, expressed by proliferating cells in all ... S, G2 and M phase). It is ... are useful in establishing the cell growing ...
... 100 g of monoclonal antibody reactive against ... of SURF1 are highest in growing cultured cells. ... c oxidase which is thought to participate in ... insertion into this subunit. Mutations of SURF1, particularly ...
Phenytoin-BSA Isolated IgY DFc Drug...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: